APA (7th ed.) Citation

Wei, M., Han, W., Zhang, J., Liu, Y., Yu, H., Li, J., & Wang, W. Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (<i>Escherichia coli</i>) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial. MDPI AG.

Chicago Style (17th ed.) Citation

Wei, Mingwei, Weiwei Han, Jing Zhang, Yongjiang Liu, Hongyang Yu, Jingxin Li, and Wenjuan Wang. Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (<i>Escherichia Coli</i>) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial. MDPI AG.

MLA (9th ed.) Citation

Wei, Mingwei, et al. Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (<i>Escherichia Coli</i>) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial. MDPI AG.